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Identification of a By-Product of Nitric Oxide
Synthase Activity in Human Acute Brain
Injury with in Vivo Proton Magnetic
Resonance Spectroscopy
Morry Silberstein, Dianne Lane, Seetal Dodd, and Kenneth Opeskin
BACKGROUND AND PURPOSE: Laboratory studies have been used to identify nitric oxide
as a notable mediator in neuronal death after acute brain injury. To our knowledge, this has not
previously been confirmed with in vivo study in humans. Our purpose was to seek in vivo
evidence for the induction of nitric oxide synthase (NOS) in human acute brain injury by using
proton MR spectroscopy.
METHODS: In vitro proton MR spectra were obtained in neural extracts from 30 human
cadavers, and in vivo spectra were obtained in 20 patients with acute brain injury and in a
similar number of control subjects.
RESULTS: We identified a unique peak at 3.15 ppm by using in vivo proton MR spectroscopy
in eight of 20 patients with acute brain injury but not in 20 healthy volunteers (P < .002). On
the basis of in vitro data, we have tentatively assigned this peak to citrulline, a NOS by-product.
CONCLUSION: To our knowledge, our findings suggest, for the first time, that excitotoxicity
may occur in human acute brain injury. Confirmation with the acquisition of spectra in very
early acute cerebral injury would provide a rationale for the use of neuroprotective agents in
these conditions, as well as a new noninvasive method for quantification.
The pathogenesis of neuronal death after injury to the
brain, from any cause, has been the subject of consid-
erable investigation. Numerous causative mechanisms
have been identified in animal models; these include
early and delayed ischemia, direct neuronal damage,
and mobilization of secondary metabolic pathways
with the production of inflammatory mediators (1).
Many of these are linked to the excitatory hypothesis,
in which brain injury from a variety of causes stimu-
lates the release of large quantities of excitatory neu-
rotransmitters—especially glutamate—that result in
an increase in intracellular calcium levels (2). This
effect is believed to activate nitric oxide synthase
(NOS), with the production of free nitric oxide (NO),
which subsequently causes DNA denaturation, energy
depletion, and cell death (1, 2). To our knowledge, this
has not been previously confirmed in humans.
Over a 5-year period of involvement in human in
vivo proton MR spectroscopy (a technique capable of
noninvasively providing metabolic information about
the brain in a range of conditions, including stroke,
infection, and neoplasms), we had examined numer-
ous patients with acute brain injury, as well as those
with metabolic and neoplastic conditions, and rou-
tinely measured relative levels of the well-described
metabolites: N-acetylaspartate, creatine, choline, lac-
tate, and glutamate (3, 4). Occasionally, in some pa-
tients with acute brain injury (including acute cere-
bral infarction, head injury, perinatal asphyxia, and
cerebral radionecrosis), we identified an additional
small spectral peak halfway between the creatine and
choline peaks. We noted these incidentally, but we
were unable to categorize them, because we were not
able to find descriptions of this peak in the literature.
In an attempt to identify this unknown peak and to
determine its importance we conducted two separate
investigations: 1) an in vitro proton MR spectroscopic
study of human brain and spinal cord neural extracts
and 2) a prospective examination of patients referred
for in vivo proton MR spectroscopy after acute brain
injury. We performed these in combination with ex-
aminations in a control group of healthy volunteers.
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Methods
Neural Extract Studies
Specimens of parietal cortex (n  7), cerebellum (n  5),
cervical spinal cord (n  15), and thoracolumbar spinal cord
(n 3) were obtained from 30 human cadavers within 48 hours
of death. These were frozen at 60°C, cut into thin strips,
lyophilized, and placed into 5-mm borosilicate tubes filled with
D2O and a known quantity of 3-trimethylsilylpropionate. With
all samples, proton MR spectroscopy was performed with a
Bruker AMX 300 machine operating at 7 T by using previously
described techniques (4). The one-dimensional spectra were
obtained at 303K by using a 30° pulse width, 6-second repeti-
tion rate, 3030-Hz sweep, 16k digital resolution, and total
acquisition over 2.7 seconds. Each spectrum was the sum of
1024 free-induction decays. The signal was processed by using
line broadening of 1 Hz and 0.05 gaussian multiplication.
Additional two-dimensional total correlation spectroscopic
(TOCSY) spectra were obtained in three samples (two brain,
one cervical cord), which were analyzed at spectroscopy by
using a 600-MHz Bruker spectrometer at 14 T, to assist with
peak assignment. No major differences in the location of peaks
were identified on visual comparison of extract spectra from
the four specimen groups.
Live Human Studies
The institutional ethics committee approval was granted
prior to study commencement, and all subjects (or guardians)
provided informed consent. Conventional MR images and sin-
gle-voxel spectra were acquired with a 1.5-T system (Vision;
Siemens, Erlangen, Germany). In the 18 healthy volunteers
(age range, 16–57 years; mean, 34.5 years) and two healthy
neonates, an 8-cm3 voxel was selected in the high parietal
region, to include both cortical grey and white matter. In the 20
patients (age range, 0–76 years; mean, 33.0 years) with acute
brain injury, which included acute cerebral infarction (n  5),
head injury (n  5), perinatal asphyxia (n  3), and cerebral
radionecrosis (n  7), examinations were conducted within 48
hours of their clinical presentation. An 8-cm3 voxel was se-
lected within the area of abnormal brain identified at conven-
tional MR imaging, and spectroscopy was performed by using
previously described techniques (3). Water suppressed proton
MR spectra were obtained with a 90°-90°-180° pulse sequence
with a 2-second interpulse delay. We used a spin-echo refocus-
sing time (TE) of 20 milliseconds, TR of 1500 milliseconds,
240  240-mm field of view, and 16  16 phase-encoding steps
with one NEX per step. Each water-suppressed spectrum was
divided by a non–water-suppressed spectrum obtained imme-
diately before, by using similar acquisition parameters, with
optimized shimming for B0 homogeneity within the selected
voxel.
Data were postprocessed by using NUMARIS software (Sie-
mens), including zero-filling to 32k, 1-Hz exponential multipli-
cation, Fourier transformation, zero-order phase correction,
and baseline correction. Spectral peaks were assigned on the
basis of previously published data, and integrated by using prior
knowledge integral shapes (3, 4). Total imaging and spectral
acquisition time averaged 53 minutes across both groups of
subjects. The presence of citrulline was defined as the clear
visualization of a discrete peak, with upward convexity, be-
tween the creatine (3.04-ppm) and choline (3.21-ppm) peaks.
Final diagnoses in the patients with acute brain injury were
established by using either histologic examination (patients
with radionecrosis) or 6-month clinical follow-up. The statisti-
cal significance of the difference between the two groups in the
observation of citrulline was calculated by using the Fisher
exact test (5). Given that the overall total of subjects numbered
40, the upper limit for this test and confirmation with a 2 test
(Yates corrected), was sought (5); both yielded an identical
result.
Results
In the in vitro spectra, in the region between the
creatine (3.04 ppm) and choline group of peaks (from
3.21 ppm) we identified a small triplet in every spec-
imen that was centred at 3.15 ppm (Fig 1A). Given
that the characteristics of this peak suggested that it
corresponded to a CH group, we subsequently ob-
tained spectra from a range of amino acids, organic
acids, and carbohydrates. The triplet corresponded
most closely to the CH2 of citrulline (Fig 1B), and
this was confirmed with a spiking experiment.
In the in vitro spectra, we could not identify any
peaks between creatine and choline in the 20 healthy
volunteers (Fig 2A). In contrast, eight patients in the
brain injury group (two with cerebral infarction, two
with head injury, one with perinatal asphyxia, three
with radionecrosis) had a visible peak between crea-
FIG 1. In vitro identification of an un-
known peak.
A, Note the small triplet (arrow) between
the creatine and choline peaks in this
magnified section of an MR spectrum ob-
tained in a cerebral cortex specimen.
B, Magnified region of this citrulline
spectrum corresponds to the shape and
location of the unknown peak.
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tine and choline centered at 3.15 ppm, which we
believe represents citrulline (Fig 2B and C). The
observed difference between the healthy volunteers
and the patients with brain injury in identification of
citrulline was highly significant (P  .002) with both
the Fisher exact test and the 2 test (Yates corrected).
We also calculated metabolite ratios for citrulline
against creatine, with values ranging from 0.023 to
0.35. No calculation of absolute values of citrulline
was possible, because relaxation parameters for this
compound are unknown at 1.5 T (4).
Discussion
The in vivo identification of citrulline in human
brain injury has major implications for the under-
standing of the pathogenesis of cerebral injury. The
brain lacks ornithine, citrulline transcarbomylase, and
carbamyl phosphate synthetase I, and is, therefore,
unable to synthesize citrulline via the urea cycle (6).
Instead, the only known method for cerebral production
of citrulline is via conversion from arginine through
NOS (2). Thus, definite demonstration of citrulline with-
in brain tissue would be indicative of the induction of
NOS, with concomitant production of NO. Our iden-
tification of substantial levels of citrulline in postmor-
tem neural extracts must reflect the profound hypoxia
that occurs at the time of death and the subsequent
massive glutamate release that results in increased
intracellular calcium levels and the induction of NOS.
While this, in itself, is of some interest, it merely
confirms the results that others (1, 2) have obtained
in living brain preparations and small animal experi-
ments by others. Far more exciting is our demonstra-
tion of a visible peak at the corresponding chemical
shift in the in vivo spectrum in human brain injury; we
have tentatively assigned this to citrulline. Confirma-
tion that this represents citrulline would prove for the
first time (to our knowledge) that excitotoxicity oc-
curs in this set of conditions. If this method were
indeed an in vivo technique for the detection of NOS
catalytic activity, one would expect a more notable
elevation of citrulline levels in the very early stages of
acute brain injury (less than 3 hours) after the insult,
and investigations of this nature are required to con-
firm our conclusions.
Are sufficient amounts of citrulline present for in
vivo MRS measurement 48 hours after injury? Or,
conversely, could the 3.15-ppm peak represent merely
noise? Although, to our knowledge, no reports of the
absolute concentrations of citrulline after brain injury
have been published, evidence of a biphasic induction
of NOS certainly exists. After injury, NO production
has an early peak, which lasts less than 1 hour, and a
delayed increase in NOS activity occurs; this reaches
its peak at 24 hours and lasts for several days (7). If
the 3.15-ppm peak represents noise, ours would prob-
ably have been the only group to observe it. We
reviewed previously published in vivo spectra in pa-
tients with acute cerebral injury and, in one of the
earliest descriptions of MR spectroscopy in acute
stroke (in 1992), we identified an unlabeled peak at
3.15 ppm in a 5-day-old cerebral infarct that was not
visible in a control spectrum on the contralateral side
(8). A similar in vitro peak was also visible in one of
the earliest published studies of MR spectroscopy in
FIG 2. In vivo identification of an unknown peak.
A, In vivo spectrum obtained in a healthy volunteer demonstrates the absence of any visible peak between those of creatine and
choline.
B, Spectrum from an area of histologically proven radionecrosis in a 22-year-old man demonstrates a small peak centered at 3.15 ppm
(arrow).
C, Spectrum from an area of suspected infarction (confirmed at 6-month clinical follow-up) in a 58-year-old woman demonstrates a
large citrulline peak between those of creatine and choline.
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rabbit cerebral autolysis (in 1988), in which a 3.15-
ppm peak was not present in an extract obtained 30
minutes after death, but it was clearly visible (al-
though not labelled) at 24 hours after death (4).
Our failure to visualize the proposed citrulline
peak in some patients could be explained by the
relatively low sensitivity of in vivo MR spectroscopy,
but the variable response to selective glutamate N-
methyl-D-aspartate (NMDA) receptor antagonists
and NOS inhibitors in patients with acute brain injury
may also be due to nonuniform induction of NOS (1).
Early quantification of NOS activity may be proven
useful in the selection of patients who are likely to
respond to these agents (9). In addition, we now have a
notable rationale for the routine examination of patients
with acute brain injury with MRS, given that infor-
mation about the pathogenesis of neuronal death may
be obtained directly and noninvasively.
Conclusion
The definite identification of excitotoxicity in hu-
man acute brain injury would confirm the experimen-
tal data in animal models and provide a rationale for
the use of neuroprotective agents in these conditions.
We present in vivo proton spectroscopic data, based
on in vitro spectra on human neural extracts, that
suggest that a by-product of excitotoxicity may be
present after acute brain injury. Confirmation of our
findings with the acquisition of serial spectra in very
early acute brain injury will have profound implica-
tions on the understanding and treatment of acute
brain injury in humans.
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